Navigation Links
Triax Pharmaceuticals Launches New Mid-Potency Corticosteroid Vehicle, Locoid Lotion 0.1%
Date:8/12/2008

Locoid Lotion was recently introduced at the Summer American Academy of Dermatology Meeting, in Chicago, Illinois, for the treatment of mild-to-moderate atopic dermatitis in pediatric to adult patients. Triax Pharmaceuticals, LLC, the marketers of Locoid Lipocream (hydrocortisone butyrate 0.1%) a leading mid-potency brand in corticosteroids, recently launched the new product to cover larger and hairy affected areas with an elegant, non-greasy application to treat atopic dermatitis.

Crawford, NJ (PRWEB) August 12, 2008 -- A new product to treat http://www.locoid.com/ [atopic dermatitis] in adult to http://www.locoid.com/ [pediatric] patients as young as three months of age was recently introduced. Locoid Lotion, launched by http://www.triaxpharma.com/ [Triax Pharmaceuticals, LLC] - the marketers of the leading mid-potency corticosteroid brand Locoid Lipocream (hydrocortisone butyrate 0.1%) - is a new lotion vehicle especially designed to cover larger and hairy affected areas with an elegant, non-greasy application to treat milt to moderate atopic dermatitis. 1.

http://www.locoid.com/ [Atopic dermatitis] (AD) is very common in the United States. It affects nearly 15 million people (1% to 3% of adults and 10% to 20% of children).1, and accounts for 10 to 20 percent of all visits to dermatologists. The key symptom is pruritus (itching), leading to the description of AD as "the itch that rashes." Itching is fairly constant during daytime hours and worsens at night, causing sleep disturbances and discomfort. For parents of children with AD, it is the number one reason for days of missed work in the United States and it is a common cause of workplace disability for all adults. People who live in cities and in drier climates appear more likely to develop http://www.locoid.com/ [atopic dermatitis].2.

http://www.locoid.com/ [Locoid Lotion] and Locoid Lipocream have been formulated with high concentration of barrier-enhancing lipids. This unique feature provides skin barrier restorative properties for a wide range of patients.

Locoid® Lotion is the ONLY class 5 corticosteroid indicated for pediatric patients 3 months of age and older. It has been proven to provide significant relief of all AD symptoms in pediatric and adult patients. In 89% of patients, symptoms of skin-barrier disruption were eliminated or reduced to mild. By Day 8, average pruritis-symptom scores were reduced to less than mild2.

Topical Corticosteroids are widely used in the treatment of mild to moderate inflammatory skin diseases. Locoid® Lotion has a wide range of benefits which include the following:

  • Easy to apply and rapidly absorbed, which in turn, makes it easy to spread over affected areas, including large and hairy areas. The cosmetic acceptability promotes patient compliance3.
  • Promotes hydration and enhances penetration of the active drug.
  • Non-halogenated, which allows for low risk of potential side effects.
  • Unlike the majority of topical corticosteroids, Locoid® Lotion contains no irritants such as propylene glycol, lanolin, or imidurea and is formulated in a non-irritating and fragrance-free base.

Dr. Adelaide Hebert, a dermatologist based in Houston, Texas remarks, "Locoid Lotion has unique properties, and is an ideal product for certain hard to treat areas such as the chest, the arms, and the legs."

Locoid® Lotion is available by prescription through pharmacies nationwide in a 2 fl. oz. bottle (4 fl. oz. to follow soon).

Reversible HPA axis suppression may occur with the potential for corticosteroid insufficiency. Consider periodic evaluations for HPA axis suppression if applied to large surface areas or used under occlusion. Systemic effects of topical corticosteroids may also include manifestations of Cushing's syndrome, hyperglycemia, and glucosuria. Pediatric patients may be more susceptible to systemic toxicity due to their large skin surface-to-body-mass ratios. Initiate appropriate therapy if a concomitant skin infection develops. Discontinue use if irritation develops.

About Triax Pharmaceuticals, LLC
Triax Pharmaceuticals is a specialty pharmaceutical company with integrated sales, marketing, and development expertise that markets a portfolio of branded dermatological products. Triax focuses on marketing dermatology products in the United States. Triax sales force is comprised of dermatology sales professionals nationwide. Triax Pharmaceuticals, LLC recently launched its fourth product, Locoid® Lotion .

In addition to industry leader Locoid Lipocream and new Locoid® Lotion, Triax Pharmaceuticals also markets two products in the acne category:

http://www.tretinx.com/ [Tretin-X® (tretinoin)] Kit is available in 0.025% cream, 0.05% cream, 0.1% cream, 0.01% gel, and 0.025% gel. Each kit contains Tretinoin cream or gel along with two cosmetic products included at no additional cost to the patient: T3™ Foaming Cleanser and T3 Soothing Moisturizer.

http://www.minocinpac.com [Minocin® (minocycline HCl) Pellet-filled Capsules Professional Acne Care (P.A.C.)]. The MINOCIN PAC system contains a 60 count bottle of Minocin Pellet-Filled Capsules (50 mg or 100 mg) and three skincare products (at no additional cost to the patient).

1Matheson R, Kempers S, Breneman D, et al. Hydrocortisone butyrate 0.1% lotion in the treatment of atopic dermatitis in pediatric subjects. J Drugs Dermatol. 2008; 7:266-271.
2 http://www.niams.nih.gov/Health_Info/Atopic_Dermatitis/default.asp#link_b
3 Fowler JF Jr. Hydrocortisone butyrate 0.1% cream in the treatment of chronic dermatitis. Cutis 2005; 75:125-131.

For more information on Locoid® Lotion for adult to pediatric patients with atopic dermatitis, please contact Peter Volk or Aleen Hosdaghian of Triax Pharmaceuticals, LLC, 908.372.0500.
See www.locoid.com for full prescribing information.

# # #

Read the full story at http://www.prweb.com/releases/2008/08/prweb1190714.htm


'/>"/>
Source: PRWeb
Copyright©2008 Vocus, Inc.
All rights reserved  

Related medicine news :

1. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
2. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
3. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
4. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
5. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
6. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
7. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
8. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
9. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
10. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
11. Class Settlement Could Result in Considerable Savings for Certain Consumers of Prescription Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Triax Pharmaceuticals Launches New Mid-Potency Corticosteroid Vehicle, Locoid  Lotion 0.1% 
(Date:6/26/2016)... ... ... Quality metrics are proliferating in cancer care, and are derived from many ... the beholder, according to experts who offered insights and commentary in the current issue ... the full issue, click here . , For the American Society of Clinical ...
(Date:6/26/2016)... (PRWEB) , ... June 26, 2016 , ... ... fertility once they have been diagnosed with endometriosis. These women need a treatment ... also require a comprehensive approach that can help for preservation of fertility and ...
(Date:6/25/2016)... TX (PRWEB) , ... June 25, 2016 , ... ... the United States, named Dr. Sesan Ogunleye, as the Medical Director of its new ... the facility Medical Director of our new Mesquite location,” said Dr. James M. Muzzarelli, ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published June ... with. The article goes on to state that individuals are now more comfortable seeking ... common operations such as calf and cheek reduction. The Los Angeles area medical group, ...
(Date:6/24/2016)... ... June 24, 2016 , ... Global law firm Greenberg Traurig, ... Elite. The attorneys chosen by their peers for this recognition are considered among the ... Traurig Shareholders received special honors as members of this year’s Legal Elite Hall of ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... , June 26, 2016 One of ... has announced the formation of a new biotechnology company, Noxopharm Limited ... $6m in an IPO and to list on the ASX. ... candidate, NOX66, ready to enter a Phase 1 clinical study later ... designed to address one of the biggest problems facing cancer patients ...
(Date:6/26/2016)... Jazz Pharmaceuticals plc (Nasdaq: JAZZ ... Antitrust Improvements Act of 1976, as amended ("HSR"), with ... ("Celator"; Nasdaq: CPXX ) expired effective June ... As previously announced on May 31, 2016, Jazz ... under which Jazz Pharmaceuticals has commenced a tender offer ...
(Date:6/26/2016)... June 27, 2016  VMS Rehab Systems, Inc. ( ... take whatever measures required to build a strong and ... is currently listed on the OTC Markets-pink current trading ... and CEO, "We are seeing an anomaly in market ... not only by the Company, but shareholders and market ...
Breaking Medicine Technology: